Alfresa Holdings Teams With Mycenax, Kidswell Bio and Chiome for Biosimilar Manufacturing Joint Venture

• Alfresa Holdings signed a share subscription agreement to convert its wholly owned subsidiary Alfenax Biologics into a four-company joint venture.
• Alfresa and Mycenax Biotech will each own 45%; Kidswell Bio will hold 7%, while Chiome Bioscience will own 3%.
• The venture will develop a biopharmaceutical manufacturing facility in Akita, Japan, covering production from active pharmaceutical ingredients to finished drugs.
• Commercial production is targeted by the end of the fiscal year ending March 31, 2031, supporting domestic biosimilar supply.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alfresa Holdings Corporation published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.